Early stage IT and Healthcare Investing

KAI Pharmaceuticals

portfoliocompanies

company snapshot

KAI Pharmaceuticals

KAI is a clinical-stage, biopharmaceutical company whose lead peptide product candidate, KAI-4169, is in development for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). CKD-MBD is characterized by an elevation of parathyroid hormone also referred to as secondary hyperparathyroidism. KAI was acquired by Amgen in 2012.

website
www.amgen.com
Leadership
Follow The Company
Investment Team
Facebook Google+ Twitter Email LinkedIn Share